Last reviewed · How we verify
NCT04167605: BC-BOMET
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases
trial testing Bone metastasis in Breast Cancer Metastatic in 30 participants. Status unknown.
12 September 2024
Quick facts
| Lead sponsor | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 13 January 2020 |
| Primary completion | 12 September 2024 |
| Estimated completion | 12 November 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Bone metastasis
- Breast cancer metastatic to bone
Conditions studied
- Breast Cancer Metastatic — all drugs for Breast Cancer Metastatic →
- Bone Metastases — all drugs for Bone Metastases →
Sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio — full company profile →
Who can join
18 and older, female only, with Breast Cancer Metastatic or Bone Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bone metastases represent a frequent complication of some solid tumours, particularly prostate, breast and lung carcinomas. Bone metastases can cause pain and give rise to the so-called "Skeletal-related Events" (SRE) such as pathological fractures and nerve compression. Despite advances in cancer treatment in general, treatment options for bone metastases remain inadequate and generally palliative. It is therefore necessary to identify patients at "high risk" of developing metastases at an early stage of neoplastic disease in order to counteract it. Therefore, the identification of changes in the expression of proteins that could be variously involved in the progression of breast cancer is of primary importance since they could act as prognostic factors and therefore address the therapeutic strategy. The aim of the investigators is to clarify the role of de-regulation of post-translational events (such as SUMOylation) in the progression of breast cancer.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic Potential of Targeting the SUMO Pathway in Cancer.
Kukkula A, Ojala VK, Mendez LM, Sistonen L, et al · · 2021 · cited 61× · PMID 34503213 · DOI 10.3390/cancers13174402 -
Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases.
Hwang JT, Lee A, Kho C. · · 2022 · cited 49× · PMID 35563444 · DOI 10.3390/ijms23095053 -
Breast cancer bone metastasis and bone metastatic cells retain NKG2DLs intracellularly: could this be a strategy to evade immune recognition?
Gomarasca M, Maroni P, Verdelli C, Gerosa L, et al · · 2026 · PMID 41675450 · DOI 10.3389/fcell.2026.1717607
Verify or expand the search:
- PubMed search for NCT04167605
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Metastatic
Currently open trials in the same condition.
- NCT07292168 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Ex · Phase 1, PHASE2 · recruiting
- NCT06616987 — Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer · Phase 2 · recruiting
- NCT06750484 — Trial of Trastuzumab Deruxtecan in Previously Treated HER2 · Phase 2 · recruiting
- NCT06784921 — To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Pa · recruiting
- NCT07154563 — Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Ca · recruiting
Other I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio trials
Trials by the same sponsor.
- NCT07386405 — Validation and Cultural Adaptation of the KOOS-ACL Scale for the Italian Population · not yet recruiting
- NCT07352111 — High-risk Coronary Atherosclerosis in Subjects With Family History of Myocardial Infarction · NA · recruiting
- NCT07304323 — Prepare II - Predictive Model Training and External Validation · recruiting
- NCT07337499 — Comparison of Maglumi X3 SNIBE With Other Analytical Methods in Laboratory Medicine for 25-(OH)D Quantification · recruiting
- NCT06940245 — Use of Virtual Reality for the Assessment of Attentional and Reaction Abilities for Fall Risk Evaluation · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04167605 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04167605.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing